.. .. Arrhythmic-events,

. .. Complications,

E. .. Results,

. .. Appropriate-icd-interventions, Predicting factors for arrhythmia during follow-up

F. .. Discussion,

G. .. Conclusion,

H. Bibliographie-de-l'étude and .. .. ,

I. Tables and . .. Figures,

H. Rakowski, Z. Sasson, and E. D. Wigle, Echocardiographic and Doppler assessment of hypertrophic cardiomyopathy, J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr, vol.1, pp.31-47, 1988.

B. J. Maron, J. S. Gottdiener, and S. E. Epstein, Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients, Am J Cardiol, vol.48, pp.418-446, 1981.

M. S. Maron, I. Olivotto, A. G. Zenovich, M. S. Link, N. G. Pandian et al., Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction, Circulation, vol.114, pp.2232-2241, 2006.

E. D. Wigle, Z. Sasson, M. A. Henderson, T. D. Ruddy, J. Fulop et al., Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review, Prog Cardiovasc Dis, vol.28, pp.1-83, 1985.

F. A. Flachskampf, L. Badano, W. G. Daniel, R. O. Feneck, K. F. Fox et al., Recommendations for transoesophageal echocardiography: update 2010, Eur J Echocardiogr J Work Group Echocardiogr Eur Soc Cardiol, vol.15, pp.557-76, 2010.

J. J. Green, J. S. Berger, C. M. Kramer, and M. Salerno, Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy, JACC Cardiovasc Imaging, vol.5, pp.370-377, 2012.

P. Richard, P. Charron, L. Carrier, C. Ledeuil, T. Cheav et al., Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy, Circulation, vol.107, pp.2227-2259, 2003.

P. Charron, M. Arad, E. Arbustini, C. Basso, Z. Bilinska et al., Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur Heart J, vol.31, pp.2715-2741, 2010.

M. Tendera, A. Wycisk, A. Schneeweiss, L. Polooski, and J. Wodniecki, Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy, Cardiology, vol.82, pp.335-377, 1993.

M. D. Flamm, D. C. Harrison, and E. W. Hancock, Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol, Circulation, vol.38, pp.846-58, 1968.

D. R. Rosing, U. Idänpään-heikkilä, B. J. Maron, R. O. Bonow, and S. E. Epstein, Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy, Am J Cardiol, vol.55, pp.185-195, 1985.

D. R. Rosing, K. M. Kent, J. S. Borer, S. F. Seides, B. J. Maron et al., Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects, Circulation, vol.60, pp.1201-1208, 1979.

M. V. Sherrid, I. Barac, W. J. Mckenna, P. M. Elliott, S. Dickie et al., Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, vol.45, pp.1251-1259, 2005.

P. Nicod, R. Polikar, and K. L. Peterson, Hypertrophic cardiomyopathy and sudden death, N Engl J Med, vol.318, pp.1255-1262, 1988.

B. J. Maron, Hypertrophic cardiomyopathy: a systematic review, JAMA, vol.287, pp.1308-1328, 2002.

J. H. Kim, R. Malhotra, G. Chiampas, P. Hemecourt, C. Troyanos et al., Cardiac arrest during long-distance running races, N Engl J Med, vol.366, pp.130-170, 2012.

B. J. Maron, Sudden death in young athletes, N Engl J Med, vol.349, pp.1064-75, 2003.

B. J. Maron, W. K. Shen, M. S. Link, A. E. Epstein, A. K. Almquist et al., Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy, N Engl J Med, vol.342, pp.365-73, 2000.

I. Jayatilleke, A. Doolan, J. Ingles, M. Mcguire, V. Booth et al., Long-term followup of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy, Am J Cardiol, vol.93, pp.1192-1196, 2004.

A. Schinkel, P. A. Vriesendorp, E. Sijbrands, L. Jordaens, F. J. Cate et al., Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis, Circ Heart Fail, vol.5, pp.552-561, 2012.

M. V. Sherrid and J. P. Daubert, Risks and challenges of implantable cardioverter-defibrillators in young adults, Prog Cardiovasc Dis, vol.51, pp.237-63, 2008.

B. J. Maron, W. J. Mckenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn et al.,

, American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines, J Am Coll Cardiol, vol.42, pp.1687-713, 2003.

B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer et al., ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, vol.58, pp.2703-2741, 2011.

L. Monserrat, P. M. Elliott, J. R. Gimeno, S. Sharma, M. Penas-lado et al., Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients, J Am Coll Cardiol, vol.42, pp.873-882, 2003.

N. Sadoul, K. Prasad, P. M. Elliott, S. Bannerjee, M. P. Frenneaux et al., Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy, Circulation, vol.96, pp.2987-91, 1997.

P. Spirito, P. Bellone, K. M. Harris, P. Bernabo, P. Bruzzi et al., Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy, N Engl J Med, vol.342, pp.1778-85, 2000.

P. Spirito, C. Autore, C. Rapezzi, P. Bernabò, R. Badagliacca et al., Syncope and risk of sudden death in hypertrophic cardiomyopathy, Circulation, vol.119, pp.1703-1713, 2009.

O. 'mahony, C. Jichi, F. Pavlou, M. Monserrat, L. Anastasakis et al., A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD), Eur Heart J, vol.35, pp.2010-2030, 2014.

. Authors/task-force-members, P. M. Elliott, A. Anastasakis, M. A. Borger, M. Borggrefe et al., ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, vol.35, pp.2733-79, 2014.

P. Magnusson, F. Gadler, P. Liv, and S. Mörner, Hypertrophic Cardiomyopathy and Implantable Defibrillators in Sweden: Inappropriate Shocks and Complications Requiring Surgery, J Cardiovasc Electrophysiol, vol.26, pp.1088-94, 2015.

O. 'mahony, C. Lambiase, P. D. Quarta, G. Cardona, M. Calcagnino et al., The longterm survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy, Heart Br Card Soc, vol.98, pp.116-141, 2012.

B. J. Maron, P. Spirito, W. Shen, T. S. Haas, F. Formisano et al., Implantable cardioverterdefibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy, JAMA, vol.298, pp.405-417, 2007.

A. J. Moss, C. Schuger, C. A. Beck, M. W. Brown, D. S. Cannom et al., Reduction in inappropriate therapy and mortality through ICD programming, N Engl J Med, vol.367, pp.2275-83, 2012.

J. Jiménez-candil, J. Hernández, A. Martín, M. Ruiz-olgado, J. Herrero et al., Influence of beta-blocker therapy on antitachycardia pacing effectiveness for monomorphic ventricular tachycardias occurring in implantable cardioverter-defibrillator patients: a dosedependent effect. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol, vol.12, pp.1231-1239, 2010.

P. A. Vriesendorp, A. Schinkel, J. Van-cleemput, R. Willems, L. Jordaens et al., Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications, Am Heart J, vol.166, pp.496-502, 2013.

B. D. Roberts, R. E. Hood, M. M. Saba, T. M. Dickfeld, A. P. Saliaris et al., Defibrillation threshold testing in patients with hypertrophic cardiomyopathy, Pacing Clin Electrophysiol PACE, vol.33, pp.1342-1348, 2010.

A. K. Almquist, J. V. Montgomery, T. S. Haas, and B. J. Maron, Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy, Heart Rhythm Off J Heart Rhythm Soc, vol.2, pp.814-823, 2005.

J. S. Healey, S. H. Hohnloser, M. Glikson, J. Neuzner, P. Mabo et al., Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE), Lancet Lond Engl, vol.385, pp.785-91, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01132536

T. Perrin, A. Mechulan, S. Boveda, F. Beganton, P. Defaye et al., Does defibrillation testing influence outcomes after CRT-D implantation? A cause-of-death analysis from the DAI-PP study, Int J Cardiol, vol.221, pp.951-957, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01414470

Y. Arnson, M. Suleiman, M. Glikson, R. Sela, M. Geist et al., Role of defibrillation threshold testing during implantable cardioverter-defibrillator placement: data from the Israeli ICD Registry, Heart Rhythm Off J Heart Rhythm Soc, vol.11, pp.814-835, 2014.

K. Phan, H. Ha, P. Kabunga, M. J. Kilborn, E. Toal et al., Systematic Review of Defibrillation Threshold Testing at De Novo Implantation, Circ Arrhythm Electrophysiol, vol.9, p.3357, 2016.

P. Charron, M. Arad, E. Arbustini, C. Basso, Z. Bilinska et al., Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur Heart J, vol.31, pp.2715-2741, 2010.

C. Rickers, N. M. Wilke, M. Jerosch-herold, S. A. Casey, P. Panse et al., Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy, Circulation, vol.112, pp.855-61, 2005.

P. Melacini, B. J. Maron, F. Bobbo, C. Basso, B. Tokajuk et al., Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy, Heart Br Card Soc, vol.93, pp.708-718, 2007.

W. J. Mckenna, C. M. Oakley, D. M. Krikler, and J. F. Goodwin, Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia, Br Heart J, vol.53, pp.412-418, 1985.

M. D. Flamm, D. C. Harrison, and E. W. Hancock, Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol, Circulation, vol.38, pp.846-58, 1968.

M. Tendera, A. Wycisk, A. Schneeweiss, L. Polooski, and J. Wodniecki, Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy, Cardiology, vol.82, pp.335-377, 1993.

O. P. Guttmann, M. S. Rahman, O. 'mahony, C. Anastasakis, A. Elliott et al., Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review, Heart Br Card Soc, vol.100, pp.465-72, 2014.

B. J. Maron, P. Spirito, W. Shen, T. S. Haas, F. Formisano et al.,

, Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy, JAMA, vol.298, issue.4, pp.405-417, 2007.

A. Schinkel, P. A. Vriesendorp, E. Sijbrands, and L. Jordaens,

M. Michels, Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. Circ Heart Fail, vol.5, pp.552-561, 2012.

P. Magnusson, F. Gadler, P. Liv, and S. Mörner, Hypertrophic Cardiomyopathy and Implantable Defibrillators in Sweden: Inappropriate Shocks and Complications Requiring Surgery, J Cardiovasc Electrophysiol, vol.26, issue.10, pp.1088-94, 2015.

O. 'mahony, C. Lambiase, P. D. Quarta, G. Cardona, M. Calcagnino et al., The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy, 2012.

P. A. Vriesendorp, A. Schinkel, J. Van-cleemput, R. Willems, L. Jordaens et al., Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications, Am Heart J, vol.166, issue.3, pp.496-502, 2013.

J. S. Healey, S. H. Hohnloser, M. Glikson, J. Neuzner, P. Mabo et al.,

, Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE), vol.385, pp.785-91, 2015.

T. Perrin, A. Mechulan, S. Boveda, F. Beganton, P. Defaye et al., Does defibrillation testing influence outcomes after CRT-D implantation? A cause-of-death analysis from the DAI-PP study, Int J Cardiol, vol.221, pp.951-957, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01414470

K. Phan, H. Ha, P. Kabunga, M. J. Kilborn, E. Toal et al., Systematic Review of Defibrillation Threshold Testing at De Novo Implantation, Circ Arrhythm Electrophysiol, vol.9, issue.4, p.3357, 2016.

Y. Arnson, M. Suleiman, M. Glikson, R. Sela, M. Geist et al., Role of defibrillation threshold testing during implantable cardioverter-defibrillator placement: data from the Israeli ICD Registry, Heart Rhythm Off J Heart Rhythm Soc, vol.11, issue.5, pp.814-835, 2014.

A. K. Almquist, J. V. Montgomery, T. S. Haas, and B. J. Maron, Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy, Heart Rhythm Off J Heart Rhythm Soc, vol.2, issue.8, pp.814-823, 2005.

B. D. Roberts, R. E. Hood, M. M. Saba, T. M. Dickfeld, A. P. Saliaris et al., Defibrillation threshold testing in patients with hypertrophic cardiomyopathy, Pacing Clin Electrophysiol PACE, vol.33, issue.11, pp.1342-1348, 2010.

B. J. Maron, W. J. Mckenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn et al., American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines, J Am Coll Cardiol, vol.42, issue.9, pp.1687-713, 2003.

B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer et al., , 2011.

, ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, vol.58, issue.25, pp.2703-2741, 2011.

O. 'mahony, C. Jichi, F. Pavlou, M. Monserrat, L. Anastasakis et al., A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD), Eur Heart J, vol.35, issue.30, pp.2010-2030, 2014.

. Authors/task-force-members, P. M. Elliott, A. Anastasakis, M. A. Borger, M. Borggrefe et al., ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, vol.35, issue.39, pp.2733-79, 2014.

A. Fernández, A. Quiroga, J. P. Ochoa, M. Mysuta, J. H. Casabé et al., Validation of the 2014 European Society of Cardiology Sudden Cardiac Death Risk Prediction Model in Hypertrophic Cardiomyopathy in a Reference Center in South America, Am J Cardiol, vol.118, issue.1, pp.121-127, 2016.

P. A. Vriesendorp, A. Schinkel, M. Liebregts, D. Theuns, J. Van-cleemput et al.,

F. J. Cate, Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy, Circ Arrhythm Electrophysiol, vol.8, issue.4, pp.829-864, 2015.

B. J. Maron, S. A. Casey, R. H. Chan, R. F. Garberich, E. J. Rowin et al., Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy, Am J Cardiol, vol.116, issue.5, pp.757-64, 2015.

A. J. Moss, C. Schuger, C. A. Beck, M. W. Brown, D. S. Cannom et al., Reduction in inappropriate therapy and mortality through ICD programming, N Engl J Med, vol.367, issue.24, pp.2275-83, 2012.

M. Gasparini, A. Proclemer, C. Klersy, A. Kloppe, M. Lunati et al., Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial, JAMA, vol.309, issue.18, pp.1903-1914, 2013.

T. A. Dewland, C. N. Pellegrini, Y. Wang, G. M. Marcus, E. Keung et al., Dualchamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry, J Am Coll Cardiol, vol.58, issue.10, pp.1007-1020, 2011.

G. H. Bardy, W. M. Smith, M. A. Hood, I. G. Crozier, I. C. Melton et al., An entirely subcutaneous implantable cardioverter-defibrillator, N Engl J Med, vol.363, issue.1, pp.36-44, 2010.

P. D. Lambiase, C. Barr, D. Theuns, R. Knops, P. Neuzil et al., Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry, Eur Heart J, vol.35, issue.25, pp.1657-65, 2014.

F. Tjong, T. F. Brouwer, L. Smeding, K. M. Kooiman, J. R. De-groot et al., Combined leadless pacemaker and subcutaneous implantable defibrillator therapy: feasibility, safety, and performance. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol, vol.18, pp.1740-1747, 2016.